Table 1 Comparison of MIS-C patients in the IVIG monotherapy versus IVIG + anakinra groups
Parameter | All MIS-C | IVIG monotherapy | All IVIG + anakinra | p-value |
|---|---|---|---|---|
Patients (n, %) | 46, 100% | 14, 30% | 32, 70% | N/A |
Demographics | Â | Â | Â | Â |
Age, in years [Q1, Q3] | 8 [4,13] | 10.5 [3.5, 13] | 8 [4, 10] | 0.57 |
Male (n, %) | 25, 54% | 8, 57% | 17, 53% | > 0.99 |
African American (n, %) | 25, 54% | 8, 57% | 17, 53% | > 0.99 |
Latin-American (n, %) | 20, 43% | 6, 43% | 14, 44% | > 0.99 |
Caucasian (n, %) | 1, 2% | 0, 0% | 1, 3% | > 0.99 |
MIS-C clinical features | Â | Â | Â | Â |
SARS-CoV2 PCR + (n, %) | 19, 41% | 5, 36% | 14, 44% | 0.75 |
Non-specific (n, %) | 15, 33% | 9, 64% | 6, 19% | 0.005 |
KD-like (n, %) | 20, 43% | 3, 21% | 17, 53% | 0.06 |
CV shock (n, %) | 23, 50% | 3, 21% | 20, 63% | 0.02 |
KDSS-like (n, %) | 12, 26% | 1, 7% | 11, 34% | 0.07 |
Medications | Â | Â | Â | Â |
IVIG (n, %) | 46, 100% | 14, 100% | 32, 100% | N/A |
Inflammatory steroids (n, %) | 3, 7% | 0, 0% | 3, 9% | 0.54 |
Stress hydrocortisone (n, %) | 7, 15% | 1, 7% | 6, 19% | 0.41 |